Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 11/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.49 |
| ▸ | PLAAT3 | P53816 | 2/20 | 0.48 |
| ▸ | PLAAT5 | Q96KN8 | 2/20 | 0.48 |
| ▸ | PLAAT2 | Q9NWW9 | 2/20 | 0.48 |
| ▸ | PLAAT4 | Q9UL19 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2066307 | 0.80 | MAPT (0.66) | HDAC1HDAC2HDAC6HDAC3HDAC4 | |
| SCHEMBL29676744 | 0.79 | MAPT (0.62) | HDAC1HDAC2TAAR1HDAC6HDAC3 | |
| SCHEMBL2067295 | 0.79 | MAPT (0.62) | HDAC1HDAC2TAAR1HDAC6HDAC3 | |
| SCHEMBL7373043 | 0.78 | HDAC1 (0.72) | HDAC1HDAC2HDAC6HDAC3HDAC4 | |
| SCHEMBL19524669 | 0.78 | TAAR1 (0.65) | TAAR1 | |
| SCHEMBL30559640 | 0.77 | TAAR1 (0.57) | HDAC1HDAC2TAAR1HDAC6HDAC8 | |
| SCHEMBL7369298 | 0.76 | HDAC1 (0.53) | HDAC1HDAC2HDAC6HDAC3HDAC4 | |
| SCHEMBL3397240 | 0.75 | TAAR1 (0.50) | TAAR1 | |
| SCHEMBL7109146 | 0.75 | TAAR1 (0.50) | HDAC1TAAR1HDAC6 | |
| SCHEMBL22190387 | 0.74 | HDAC1 (0.67) | HDAC1HDAC2HDAC6HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383652-B2 | Biaromatic compounds that modulate PPAR-receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-02-26 | — | — | US | disclosed |
| US-20090012129-A1 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012129-A1 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS | PPARG, PPARD, PPARA | HDAC1 240/4885HDAC2 266/4885TAAR1 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.